Print health ad spending rises in January; Novo program fights urban diabetes;

> Print health ad spending in the U.S. totaled $45 million in January, a 7% year-on-year increase. Report

> Novo Nordisk ($NVO) has launched "Cities Changing Diabetes," a partnership program to fight urban diabetes. Release

> BioAlliance Pharma has fired Oravig marketing partner Vestiq Pharmaceutical and has updated its marketing partnership for Loramyc. Release

> Stallergenes has won FDA approval for Oralair, an immunotherapy allergy tablet that will be marketed by Greer. Release

> With Sanofi Oncology's ($SNY) "Strollin' Colon" display, onlookers can walk through a giant inflatable colon and learn about the colorectal cancer screening process. More

> Johnson & Johnson Middle East ($JNJ) has teamed up with Impact BBDO Dubai to create a grandparents-only app and digital photo frame that receives and displays photos of grandchildren. More

> Specialty pharma Clinigen Group has acquired Savene, an oncology support therapy, from SpePharm AG. Release

And Finally... What is a patent troll? Congress, courts try to find out. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The U.S. aesthetics business is booming with fillers and fat freezers garnering interest, and spurring marketing campaigns, post-lockdown COVID-19.